PrEP-ared for Surgery? A Comprehensive Narrative Review of Perioperative Recommendations for Anesthesia Providers.

Overview

abstract

The use of Pre-Exposure Prophylaxis (PrEP) for human immunodeficiency virus (HIV) prevention has increased significantly, with approximately 30% of eligible individuals in the U.S. receiving a prescription by 2021, up from 13% in 2017. As more patients on PrEP undergo surgical procedures, understanding the perioperative implications of these medications is crucial for anesthesia providers. This review aims to summarize current literature on the perioperative considerations for patients on PrEP and provide anesthesia providers with key recommendations to optimize patient safety and outcomes. It examines the pharmacology, side effects, and perioperative considerations of current PrEP formulations: Truvada, Descovy, and Apretude. We conducted a broad literature search focusing on publications from 2013 through 2024. The review identifies potential nephrotoxicity with tenofovir-based formulations, particularly when combined with nephrotoxic agents such as nonsteroidal anti-inflammatory drugs. Emtricitabine/tenofovir alafenamide use is associated with an increased risk of hypertension and hypercholesterolemia. No specific anesthetic agents are contraindicated, but dose adjustments for renally excreted drugs may be necessary. Current evidence supports continuing PrEP throughout the perioperative period, with strategies provided for managing different formulations during surgery. As PrEP use expands, anesthesia providers must balance safe, effective care with contributing to HIV prevention efforts. Future research should focus on long-term anesthetic implications of PrEP and optimal perioperative management strategies. By implementing informed practices, anesthesia providers can significantly enhance the care of patients on PrEP and support broader public health goals in HIV prevention.